Advanced Search
MyIDEAS: Login to save this paper or follow this series

Entry in the ADHD drugs market: Welfare impact of generics and me-toos


Author Info

  • Farasat A.S. Bokhari

    (Department of Economics, Florida State University)

  • Gary M. Fournier

    (Department of Economics, Florida State University)


Recent years have seen the growing popularity of drugs designed to treat attention deficit hyperactivity disorder (ADHD), and the number of patients, scripts, and revenues has been steadily increasing. By the mid-1990s there were already several branded drugs marketed for this disorder, as well as numerous generic formulations. With the expansion of the market in the late 1990s and early 2000s, new formulations (the so called `me-too' drugs) entered and caused dramatic changes in the distribution of market shares among available drugs. Using detailed sales data on psychostimulant drugs used to treat ADHD, we are able to identify and measure substitution patterns across a range of drugs. We find that the demand for ADHD drugs is fairly elastic and there are significant substitution possibilities among these drugs. Using estimates from demand parameters, we show that the first-time introduction of a generic drug can have large welfare gains due to the expansion of the market to price sensitive consumers. Additionally, the welfare gains due to the introduction of me-too drugs vary by the novelty of the drug, and for significantly new varieties can be larger than those of the introduction of a generic. Our results bear policy implications for both the speed with which new drugs are approved for marketing as well as for actions among pharmaceutical firms that may delay the entry of a generic drug.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL:
File Function: First version, 2009-05
Download Restriction: no

Bibliographic Info

Paper provided by Department of Economics, Florida State University in its series Working Papers with number wp2009_05_01.

as in new window
Length: 43 pages
Date of creation: May 2009
Date of revision:
Handle: RePEc:fsu:wpaper:wp2009_05_01

Contact details of provider:
Postal: 246 Bellamy Building, Tallahassee, Florida 32306-2180
Phone: 850-644-5001
Fax: 644-4535
Web page:
More information through EDIRC

Order Information:

Related research

Keywords: Differentiated products demand; multistage budgeting; AIDS model; psychostimulant drugs; new introductions; welfare analysis;

Other versions of this item:

Find related papers by JEL classification:

This paper has been announced in the following NEP Reports:


No references listed on IDEAS
You can help add them by filling out this form.


Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as in new window

Cited by:
  1. Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013. "Pharmaceutical followers," International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
  2. Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
  3. Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich‐Heine‐Universität Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).


This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.


Access and download statistics


When requesting a correction, please mention this item's handle: RePEc:fsu:wpaper:wp2009_05_01. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dmitry Ryvkin).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.